![]() |
市场调查报告书
商品编码
1495997
全球酵素结合免疫吸附检测法(ELISA) 市场 - 2024 年至 2029 年预测Global Enzyme-Linked Immunosorbent Assay (ELISA) Market - Forecasts from 2024 to 2029 |
酵素结合免疫吸附检测法(ELISA) 市场预计将以 5.56% 的复合年增长率成长,从 2022 年的 21.38 亿美元增至 2029 年的 31.23 亿美元。
ELISA(酵素结合免疫吸附检测法)或酵素免疫分析法测定(EIA)是一种基于板的测量技术,旨在检测和定量胜胜肽、蛋白质、抗体和荷尔蒙等物质。 ELISA 通常用作更详细测试之前的筛检工具。由于 ELISA 反应物固定在微孔盘表面,因此在测定过程中可以轻鬆分离结合和未结合的物质。这使其成为测定粗製剂中特定分析物的强大工具。
ELISA 的常见诊断用途包括 HIV 感染、怀孕检测和蛋白质检测。预计 ELISA 市场在预测期内将稳定成长。这种增长可能是由于感染疾病和慢性病患病率的上升以及对 ELISA 作为具有成本效益的诊断工具的需求。然而,有关 ELISA 的严格监管要求和不利的报销政策可能会阻碍预测期内的市场成长。
推动市场扩张的关键因素之一是爱滋病毒、肝炎、疟疾、登革热和流感等感染疾病率的上升。世界卫生组织估计,到 2021年终,全球有 3,840 万名爱滋病毒感染者,其中三分之二以上居住在非洲。世界卫生组织也声称,登革热是世界面临的十大健康威胁之一。过去 50 年来,全球登革热发生率增加了约 3,000%。世界卫生组织也估计,2019 年全球有超过 2.96 亿人感染B型肝炎。
由于感染疾病发生率不断增加,对诊断的需求预计也会增加。由于越来越多地使用尖端诊断技术(例如酵素结合免疫吸附测试)来筛检这些疾病,预计该市场将会扩大。
此外,全球越来越多的老年人患有感染疾病和慢性病的高风险并需要常规诊断,预计将刺激市场扩张。根据 NCBI(美国生物技术资讯中心)于 2021 年发布的消息,与年轻人相比,老年患者更有可能发生潜在危险的疾病。因此,这些因素预计将增加对酵素结合免疫吸附检测法的需求,从而显着提高市场成长。
越来越多地使用酵素结合免疫吸附测定测试来诊断特定抗原,预计将占据疾病诊断市场的重要份额。世界卫生组织估计,到 2022 年,非传染性疾病每年将导致约 4,100 万人死亡,占全球死亡人数的 71%。此类疾病的发生增加了对有效诊断技术(例如用于快速检测的 ELISA)的需求,以最大限度地降低死亡率。
此外,根据全球癌症观察站的数据,2020年将有约1,930万人新诊断出癌症,约1,000万人将死于癌症。由于 ELISA 是评估抗原的有用工具,全球癌症发生率的上升正在推动其需求。
根据 Nature Scientific 2020 年的一项研究,酵素结合免疫吸附检测法可用于寻找乳腺癌和前列腺癌抗原。这种准确的抗原筛检和具有成本效益的诊断预计将在分析期间增加 ELISA 需求并推动市场扩张。
预计北美将占据很大的市场份额
由于ELISA等筛检设备技术突破的市场开拓迅速,美国很可能主导全球市场。该地区多种感染疾病和慢性疾病的发生率不断增加,增加了对酵素酵素结合免疫吸附检测法的需求。例如,美国疾病管制与预防中心 (CDC) 报告称,到 2022 年,超过 60% 的美国人将患有至少一种慢性疾病,例如癌症、心血管疾病或中风。
由于研发支出的增加和诊断资金的大量投入,预计该地区的市场将会成长。根据 Binder Dijker Otte USA 2020 年报告,生技指数中的上市公司 2020 年研发支出平均成长约 16% 至 2.8425 亿美元。
此外,2021 年,美国卫生与公众服务部宣布从美国救援计画中拨款 6.5 亿美元,用于提高快速、高品质诊断测试的生产能力。因此,所有这些方面预计将在预测期内很好地支持北美区域市场。
The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 5.56% increasing from US$2.138 billion in 2022 to US$3.123 billion in 2029.
ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface, making it easy to separate bound from non-bound material during the assay. This makes it a powerful tool for measuring specific analytes within a crude preparation.
The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavorable reimbursement policies about ELISA, might hamper the market growth during the given time frame.
One of the key drivers fuelling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.
The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand due to the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.
Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.
Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. In 2022, the WHO estimated that non-communicable illnesses caused around 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences.
Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it.
The Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.
North America is Expected to Hold a Significant Share in the Market
Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.
The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020.
Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.